Competition to cross the so-called Valley of Death has become rather stiff at the National Institutes of Health (NIH).
Since 2009, the NIH's Therapeutics for Rare and Neglected Diseases (TRND) program has solicited proposals from scientists and pharmaceutical companies trying to navigate that dead zone between discovering promising compounds and getting them into human clinical trials. To date, TRND has received 125 applications for nonmonetary assistance; 10 have gotten the green light.
Voelker R. NIH Program Helps Developers Navigate Path to New Drugs for Neglected Diseases. JAMA. 2012;307(6):549–550. doi:10.1001/jama.2012.83
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: